In the event of a radiation leak or nuclear accident, oral medication options are needed for quick-turnaround, effective, large-scale treatment.
Drug development services
SRI International’s continuous flow SynFini™ Suite produced multiple nucleoside antivirals in a single day.
SRI scientists partner with Mapp Biopharmaceutical to accelerate FDA approval for clinical trials.
SRI scientists collaborate with Lawrence Berkeley National Laboratory to chart a path for obtaining regulatory approval for a clinical development plan for a novel decorporation agent.
MENLO PARK, Calif., November 23, 2020 — SRI International has been awarded a contract of up to $107 million from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases and the Division of AIDS (NIAID-DAIDS) to support basic and pre-clinical research and therapeutic product development for human immunodeficiency virus (HIV), Mycobacterium tuberculosis (MTB) complex, and hepatitis […]
SRI International awarded $40 million NICHD contract for pre-clinical development of new male and female contraceptive products
MENLO PARK, Calif.—October 28, 2020— SRI International has been awarded a Biological Testing Facility (BTF) contract of up to $40 million from the Eunice Kennedy Shriver Institute of Child Health and Human Development (NICHD) to complete discovery and preclinical development of new contraceptive compounds. Under the five-year contract, SRI is responsible for all preclinical support […]
SRI International has been awarded a National Science Foundation (NSF) grant through the Grants for Rapid Response (RAPID) program. RAPID is a mechanism used by the NSF to provide funds for urgent research that addresses unexpected disasters or events such as the COVID-19 pandemic. SRI scientists will use the RAPID grant to develop a first-of-its-kind […]